Lipid accumulation in organs is strongly associated with insulin resistance. However, the causal relationship is uncertain. For hepatic steatosis, this relationship has given rise to many studies and theories. One hypothesis, suggested as unifying (1), posits simply that accumulation of diacylglycerol induces hepatic insulin resistance by interfering with insulin signaling.
Lipid accumulation in organs is strongly associated with insulin resistance. However, the causal relationship is uncertain. For hepatic steatosis, this relationship has given rise to many studies and theories. One hypothesis, suggested as unifying (1) , posits simply that accumulation of diacylglycerol induces hepatic insulin resistance by interfering with insulin signaling.
We previously tested the relationship between hepatic steatosis and insulin resistance by generating transgenic mice that overexpress triacylglycerol (TG) synthesis enzymes [acyl-CoA: diacylglcyerol acyltransferases (DGATs)] in the liver (2) . Analysis of two lines that overexpressed DGAT2 (low-and high-expressors) refuted the DG hypothesis: hepatic DG accumulation (and other lipids such as TG, fatty acyl CoAs, and ceramides) did not lead to insulin resistance. We extensively analyzed the low-expressor line. Multiple cohorts of mice studied in several laboratories showed normal values for blood glucose and insulin, glucose-and insulin-tolerance tests, hyperinsulinemic-euglycemic clamps, and multiple assays of insulin signaling.
In PNAS (3), Jornayvaz et al. reclamped the same DGAT2 low-expressor line and reported that steatosis was associated with hepatic insulin resistance.
What could account for the different results? One possibility might be differences in lipid levels. We found fivefold more TG and approximately 1.5-fold more DG in DGAT2 lowexpressors (2.1-fold increase) than controls. Jornayvaz et al. (3) found a modest two-to threefold increase in TG and an approximately 12-fold increase in DG. From the biochemistry of DGATs, it is difficult to explain why DGAT2 overexpression would yield a disproportionate accumulation of its substrate relative to its product (i.e., TG). Interestingly, and potentially as a consequence of these differences in hepatic lipids, Jornayvaz et al. (3) found abnormalities with hyperinsulinemiceuglycemic clamps (performed with 3 mU/kg/min insulin). We found normal insulin sensitivity with this assay (2 mU/kg/min insulin). However, clamp studies are fraught with difficulties in murine models (4), and differences in clamp methodology might have contributed to the discrepancy. Phenotyping centers recommend that clamps be done with multiple other measurements of insulin and glucose metabolism, as we did. Jornayvaz et al. (3) did not perform glucose-or insulin-tolerance tests, and insulin signaling assays were limited in scope and performed with the clamp experiment. Notably, we also found normal glucose and insulin tolerance in DGAT2 high-expressors (17-and 3-fold increases in TG and DG, respectively).
How do the same transgenic mice show such discrepant phenotypes in different laboratories? Possible differences include the genetic backgrounds [C57BL/6NHsd for our group (2) and unspecified for Jornayvaz et al. (3) ] or the diet [Ralston Purina chow diet for our group (2) vs. Harlan Teklad chow diet for Jornayvaz et al. (3)]. Could such minor differences, including different environments in institutional animal facilities, explain such large differences in phenotypes? If so, it highlights concerns for mouse metabolism and clamp studies (4) .
In the larger perspective, we note that the hypothesis that DG accumulation is sufficient to drive insulin resistance is refuted by a single counterexample. In fact, numerous other studies also refute it (e.g., ref. 5). We suggest therefore that future studies consider a more refined approach, including measuring specific DG species and their cellular and intracellular compartmentalization, when testing hepatic steatosis models. 
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